» Articles » PMID: 32161718

Tumor-Associated Macrophages: Recent Insights and Therapies

Overview
Journal Front Oncol
Specialty Oncology
Date 2020 Mar 13
PMID 32161718
Citations 320
Authors
Affiliations
Soon will be listed here.
Abstract

Macrophages, which have functions of engulfing and digesting foreign substances, can clear away harmful matter, including cellular debris and tumor cells. Based on the condition of the internal environment, circulating monocytes give rise to mature macrophages, and when they are recruited into the tumor microenvironment and in suitable conditions, they are converted into tumor-associated macrophages (TAMs). Generally, macrophages grow into two main groups called classically activated macrophages (M1) and alternatively activated macrophages (M2). M2 and a small fraction of M1 cells, also known as TAMs, not only lack the function of phagocytizing tumor cells but also help these tumor cells escape from being killed and help them spread to other tissues and organs. In this review, we introduce several mechanisms by which macrophages play a role in the immune regulation of tumor cells, including both killing factors and promoting effects. Furthermore, the targeted therapy for treating tumors based on macrophages is also referred to in our review. We confirm that further studies of macrophage-focused therapeutic strategies and their use in clinical practice are needed to verify their superior efficacy and potential in cancer treatment.

Citing Articles

Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy.

Almawash S Cancers (Basel). 2025; 17(5).

PMID: 40075727 PMC: 11899125. DOI: 10.3390/cancers17050880.


Stroma AReactive Invasion Front Areas (SARIFA), tumour immune microenvironment, and survival in colorectal cancer.

Tapiainen V, Sirnio P, Elomaa H, Karjalainen H, Aijala V, Kastinen M Br J Cancer. 2025; .

PMID: 40055484 DOI: 10.1038/s41416-025-02972-z.


Tumor-Associated Macrophage (TAM)-Related Cytokines, sCD163, CCL2, and CCL4, as Novel Biomarkers for Overall Survival and Time to Treatment in Waldenstrom's Macroglobulinemia: Emphasis on Asymptomatic WM.

Gkiokas A, Papadatou-Gigante M, Gkioka A, Koudouna A, Tryfou T, Alexandropoulos A Cells. 2025; 14(4).

PMID: 39996747 PMC: 11853255. DOI: 10.3390/cells14040275.


Cell fusion as a driver of metastasis: re-evaluating an old hypothesis in the age of cancer heterogeneity.

Lopez-Collazo E, Hurtado-Navarro L Front Immunol. 2025; 16:1524781.

PMID: 39967663 PMC: 11832717. DOI: 10.3389/fimmu.2025.1524781.


Trained immunity in chronic inflammatory diseases and cancer.

Hajishengallis G, Netea M, Chavakis T Nat Rev Immunol. 2025; .

PMID: 39891000 DOI: 10.1038/s41577-025-01132-x.


References
1.
Santoni M, Bracarda S, Nabissi M, Massari F, Conti A, Bria E . CXC and CC chemokines as angiogenic modulators in nonhaematological tumors. Biomed Res Int. 2014; 2014:768758. PMC: 4058128. DOI: 10.1155/2014/768758. View

2.
Myers K, Amend S, Pienta K . Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment. Mol Cancer. 2019; 18(1):94. PMC: 6515593. DOI: 10.1186/s12943-019-1022-2. View

3.
Yona S, Gordon S . From the Reticuloendothelial to Mononuclear Phagocyte System - The Unaccounted Years. Front Immunol. 2015; 6:328. PMC: 4486871. DOI: 10.3389/fimmu.2015.00328. View

4.
Mok S, Koya R, Tsui C, Xu J, Robert L, Wu L . Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 2013; 74(1):153-161. PMC: 3947337. DOI: 10.1158/0008-5472.CAN-13-1816. View

5.
Colombo M, Raposo G, Thery C . Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014; 30:255-89. DOI: 10.1146/annurev-cellbio-101512-122326. View